An estimated 80 million U.S. adults and 10 million U.S. children suffer from obstructive sleep apnea, and approximately ... New technology available through Vivos and SleepImage© is lowering ...

Vivos Therapeutics brings hope to the 90 million Americans affected by obstructive sleep apnea (OSA). Their FDA-cleared Vivos CARE oral devices offer a non-invasive alternative to CPAP therapy ...

The gross proceeds to the Company from the offering are expected to be approximately $3.5 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The ...

About VIVOS THERAPEUTICS Obstructive sleep apnea (OSA) affects over 1 billion people worldwide, yet 85% remain undiagnosed and unaware of their condition. This chronic disorder is not just a sleep ...

Vivos Therapeutics brings hope to the 90 million Americans affected by obstructive sleep apnea (OSA). Their FDA-cleared Vivos CARE oral devices offer a non-invasive alternative to CPAP therapy, with ...

An estimated 80 million U.S. adults and 10 million U.S. children suffer from obstructive sleep apnea, and approximately 85% of them are undiagnosed and untreated. In lab sleep testing can cost $4,000 ...